Biotech News

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid (PYPD)PolyPid2026-06-25 13:46 ESTFDA / regulatory

If approved, D-PLEX 100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the

Open original release

Related news

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Announces Participation in Upcoming Investor Conferences

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application

PYPDPolyPid2026-06-25 13:46 EST

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PYPDPolyPid2026-06-25 13:46 EST

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

View all latest news

PolyPid

PolyPid is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PYPDPolyPid2026-06-26 07:10 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-06-26 07:10 EST

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PYPDPolyPid2026-06-26 07:10 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-06-26 07:10 EST

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PYPDPolyPid2026-06-26 07:10 EST

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States